



PATENT  
ATTORNEY DOCKET NO.: 044574-5040-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Patrick C. KUNG *et al.* )  
Application No.: 09/830,033 ) Group Art Unit: 1631  
Filed: October 22, 2001 ) Examiner: Cheyne D. Ly  
For: PHYTOMICS: A GENOMIC-BASED APPROACH TO )  
HERBAL COMPOSITIONS )

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**DECLARATION UNDER 37 C.F.R. §1.132**

I, Dan Theodorescu, M.D., Ph.D., declare as follows:

1. I am presently Director of the Paul Mellon Prostate Cancer Institute, Professor of the Department of Molecular Physiology and Biological Physics, Professor of the Department of Urology, the Paul Mellon Chair in Urologic Oncology, an Attending Urologist at University Hospital, and Urologic Oncologist at the Cancer Center, all located at the University of Virginia, Charlottesville, Virginia. A copy of my curriculum vitae is attached as Exhibit A.
2. I have read and am familiar with International Patent Application No. WO 00/24934, entitled *Phytomics: A Genomic-Based Approach to Herbal Compositions*, with inventors Patrick C. KUNG and Young Chi CHENG, and applicant Yale University (“the Yale patent application”), originally filed on October 23, 1998. I have been informed that the Yale patent application is

licensed exclusively to PhytoCeutica Inc., a company headquartered in New Haven, Connecticut. The Yale patent application discloses and claims a method of evaluating the biological equivalency for the purpose of quality control of an herbal composition, wherein the method includes comparing the genomic expression pattern (*i.e.*, test bioresponse array) generated by exposing a biosystem to the herbal composition to a genomic expression pattern (*i.e.*, standardized herbal bioresponse array) collected from the same or substantially the same herbal composition that is considered the botanical standard.

3. I have reviewed and understand the claims 83 – 87 that are presently pending in the Yale patent application.
4. I have read and understand the Final Office Action that was mailed by the U.S. Patent and Trademark Office on February 24, 2004 regarding the Yale patent application, particularly paragraphs 16 – 27 on pages 5-7 (*i.e.*, the claim rejections under 35 U.S.C. § 103). It is my understanding that the Patent Examiner maintains that claims 83 – 87 are not patentable in view of the teachings of Khwaja *et al.* (U.S. Patent No. 6,113,907) in view of Schena *et al.* (Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc. Natl. Acad. Sci USA 93:10614-10619. 1996). I have read and understand Khwaja *et al.* and Schena *et al.*
5. Complementary and alternative therapies offer opportunities and novel insights for the treatment and prevention of neoplastic diseases. We have recently shown that 43% of men with localized prostate cancer (CaP) use herbal complementary therapies (Lippert, M. C., McClain, R., Boyd, J. C., and Theodorescu, D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer, 86: 2642-2648, 1999). These prevalence rates varied

as a function of age and aggressivity of the cancer. In addition, we have shown that many patients are highly motivated to use these therapies due to their relatively low toxicity profile (Hall, J. D., Bissonette, E. A., Boyd, J. C., and Theodorescu, D. Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. *BJU Int*, 91: 603-607, 2003). However, most compelling was the finding that several of these botanical therapies show striking and beneficial clinical effects on human CaP as well as in experimental in vitro studies. One such example is PC-SPES, a combination of 8 herbal extracts that has significant clinical benefits for patients with metastatic, hormone-refractory CaP.

Dr. Eric Small, an oncologist at University of California San Francisco reported in 2000 that BotanicLab's PC-SPES lowered PSA and shrank tumors in men with advanced prostate cancer. Furthermore, in 2002 Dr. Small and Dr. William Oh at Dana Farber opened a randomized trial to compare PC-SPES with Diethylstilbestrol (DES), an artificial estrogen in view of the fact that PC-SPES is known to have estrogenic effects. All of the patients had androgen independent prostate cancer; none of them had received chemotherapy or other advanced therapy. As this trial began to accrue, men who received PC-SPES actually did better than men receiving DES (although not quite as well as patients taking PC SPES in the earlier study). Patients enrolled in the PC SPES arm of the trial were showing better responses than those receiving DES. Of the PC SPES group, 45% had at least a 50% drop in PSA (prostate specific antigen, a biochemical marker of prostate cancer). Only 21% of those on DES experienced a 50% drop.

Unfortunately, and pertinent to this application, in late 2002, the aforementioned trial was stopped prematurely by the FDA because of ongoing concerns about the contents of PC-SPES. A few months before this, lots of PC-SPES tested had

small amounts of DES and other pharmaceuticals present. Although, in view of the trial design, the DES contamination of the PC-SPES would not have been a source of the improved effects of PC-SPES in patients (since the trial compared it to pure DES), nevertheless study of this very promising herbal medication was halted. This problem was further compounded by a clinical observation made by most oncologists, namely that the side effects of PC-SPES in patients seemed to depend not only on patient profiles but also on the lots of PC-SPES they were taking. Hence, this suggested that the lot to lot variability of the product was significant and that the company at that time (circa 2000-2002) despite 1) the prior publication of Khwaja *et al* and Schena *et al*; and 2) their in house quality control processes, did not have the idea or vision to formulate a quality control process based on gene expression profile which could have prevented these problems.

It is particularly important to place in perspective why nobody until our group in 2003 (Bigler, D., Gulding, K. M., Dann, R., Sheabar, F. Z., Conaway, M. R., and Theodorescu, D. Gene profiling and promoter reporter assays: novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action. *Oncogene*, 22: 1261-1272, 2003, copy attached as Exhibit B) demonstrated this approach toward quality control of herbal products and consequently why, the current patent application by Patrick C. KUNG et al. has great merit. Consider these facts: 1) The two papers quoted above (Khwaja *et al* and Schena *et al*) are in very disparate areas of science. It is not customary for someone working in botanical products to be familiar with and/or scan the gene expression molecular biology literature routinely. Science today is highly complex and specialized and significant developments on none area (as would have been the case with cDNA microarrays in 1995) were not “common knowledge” even in molecular biology circles, let alone, in individuals working in botanical products. 2) The mindset and approach of workers in the botanical field for many years and certainly in the early nineties

was very descriptive and non scientific, with scientific research (basic science) and/or clinical trials of these products being rare. 3) Our laboratory, in 2002 began work which culminated in the formulation of an approach using gene expression profiling for quality control of botanical products (Bigler reference above). It is important to understand that my laboratory and my research program is one which is fundamentally carrying out translational research and therefore is grounded in both molecular biology and clinical medicine. Thus, it was this unique combination that allowed us to formulate and synthesize the approach to combine gene expression profiling to a clinically relevant problem, made so by the unfortunate collapse of the PC-SPES trial; a trial that is completed may have produced a novel and effective therapeutic strategy for metastatic prostate cancer. In addition, it is not at all obvious that even in my lab we would have thought of this concept in 1998, the time this patent was filed. 4) Finally, despite the prior publication of Khwaja *et al* and Schena *et al* and their in house quality control processes, BotanicLab, the makers of PC-SPES, did not have the idea or vision to formulate a quality control process based on gene expression profile which could have prevented the lot to lot variability that plagued their product in 2000-2002. 5) Khwaja *et al.* disclose using compositional and bioactivity fingerprints for the processing of St. John's Wort to produce botanical drugs. Their disclosed method includes measuring selective muscarinic M1 receptor binding inhibition of samples of St. John's Wort. The methods taught by Khwaja *et al.* do not include using gene expression profiles for quality control. Schena *et al.* disclose using microarray-based expression monitoring of genes to identify known and novel heat shock and phorbol ester-regulated genes in human T cells. Schena *et al.* involves the identification of heat shock and phorbol-ester-regulated genes using microarray-based expression. They do not provide any guidance on how one would utilize a differential gene expression profile of multiple genetic components in a quality control method for assessing the equivalency of herbal compositions.

In summary, for the above 5 reasons I believe that it was NOT obvious to an artisan of ordinary skill to combine the works of Khwaja *et al* and Schena *et al* and formulate a proposal similar to the proposed patent by Patrick C. KUNG et al. in 1998.

6. As support for my position as stated in paragraph 2 above, I attach as Exhibit B a copy of an article entitled *Gene profiling and promoter reporter assays: Novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action*, (Bigler *et al.*, Oncogene 22:1261-1272 (2003)). I am a co-author of this article reporting on the results of using PC-SPES, a combination of eight herbs, “as a model system to demonstrate ‘proof of principle’ as to how gene expression profiling coupled with promoter assays can evaluate the effect of herbal cocktails on human prostate cancer” (Abstract). We realized that during these studies, and stimulated by the Quality Control (“QC”) debacle of PC-SPES in 2002 as described above, that the expression profile could in fact be a very powerful biological metric for botanical QC. Hence, we hypothesized the following:

“This finding has profound implications since it potentially offers an avenue for the molecular ‘fingerprinting’ of complex botanical extracts, which are claimed to be made from the same natural sources.

Application of these approaches in preclinical studies may allow for both the standardization of the botanical mixtures allowing for rational interpretation of any discrepant human clinical data. In addition, companies producing botanical products can use this technology in quality assurance of their products, which may have biological relevance superior to conventional approaches such as HPLC.” Page 1266, second column.

Importantly, even in this 2003 publication the original purpose of the study was to assess and compare mechanisms of action between two different botanical formulations and that the observation of the utility of using gene expression

profiles for quality control of botanicals was actually an afterthought. Thus, as mentioned above in paragraph 5, it is my belief that one of ordinary skill in the herbal medicine arts could not have arrived at the invention now claimed in the Yale application in 1998 based on the combined teachings of Khwaja *et al.* and Schena *et al.* It is also my belief that the invention now claimed in the Yale patent application could have real utility for determining an advanced form of quality control for botanical extracts and provides an important advancement in the standardization of herbal compositions.

7. I further declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:   
Dated: 3/7/05

# CURRICULUM VITAE

*Dan Theodorescu MD PhD*



## PERSONAL

LANGUAGES SPOKEN: *English, French, Romanian*  
MARITAL STATUS: *Married to Diane Louise Causier*  
CHILDREN: *Thomas William (DOB 1/26/95)*  
*Claire Ana (DOB 10/6/96)*

## CURRENT ADDRESS

Department of Urology  
University of Virginia  
Charlottesville, Virginia, 22908-0422, USA  
Tel: 434-924-0042  
Fax: 434-982-3652  
Internet: theodorescu@virginia.edu  
Web Page: <http://faculty.virginia.edu/theodorescu/>

## ACADEMIC DEGREES

1993            ***Doctor of Philosophy (PhD)***  
                  University of Toronto, Toronto, Ontario, Canada.  
1986            ***Doctor of Medicine (MD)***  
                  Queen's University, Kingston, Ontario, Canada.

## POSITIONS HELD

### *University of Virginia, Charlottesville, VA*

2003-present    *Director, Paul Mellon Prostate Cancer Institute*  
2002-present    *Professor, Department of Molecular Physiology and Biological Physics*  
2001-present    *Professor, Department of Urology*  
1998-present    *Paul Mellon Chair in Urologic Oncology, Department of Urology*  
1995-present    *Attending Urologist, University Hospital*  
1995-present    *Urologic Oncologist, Cancer Center*  
  
2001-2002       *Associate Professor, Department of Molecular Physiology and Biological Physics*  
1998-2001       *Associate Professor, Department of Urology*  
1995-2001       *Assistant Professor, Department of Molecular Physiology and Biological Physics*  
1995-1998       *Assistant Professor, Department of Urology*

## PROFESSIONAL CERTIFICATIONS

1999            Certified by the American Board of Urology  
1998            Fellow of the American College of Surgeons (*FACS*)  
1995            Medical License in the State of Virginia  
1995            Fellow of the Royal College of Physicians and Surgeons of Canada (*FRCS*)  
1994            Certified by the Royal College of Physicians and Surgeons of Canada in Urology  
1986            Licentiate of the Medical Council of Canada (*LMCC*)

**ADMINISTRATION AND COMMITTEES**

---

1995-1999	Tumor Registry Committee, University of Virginia, Charlottesville, VA
1996-1997	AFUD Bladder Health Council, USA: <i>Bladder cancer awareness week organizing committee</i>
1996-1999	ECOG Genitourinary Committee, USA
1997-1999	American Cancer Society, Prostate Cancer Planning Committee, Virginia Chapter
1999-2003	Basic Cardiovascular Research Training Grant Executive Committee, University of Virginia, Charlottesville, VA
2000	Member, Dean's Search Committee for Chairman, Department of Pathology
2001-2003	Member, Executive Management Committee, Tyco/US Surgical Laparoscopic Center of Excellence, University of Virginia, Charlottesville, VA
2001-2003	Member, Internal Advisory Board, Paul Mellon Prostate Cancer Institute, University of Virginia, Charlottesville, VA
2001-present	Member, Cancer Center Seminar Series Committee, University of Virginia, Charlottesville, VA
2003-present	Member, American Urological Association (AUA) Research Council.
2003-present	Director, Paul Mellon Prostate Cancer Institute
2004-2007	Nominations Committee for the Society for Basic Urology Research (SBUR)

**MEMBERSHIPS IN PROFESSIONAL ASSOCIATIONS**

---

2001-present	European Association of Urology (EAU)
1998-present	American College of Surgeons (ACS)
1998-present	Society for Urologic Oncology (SUO)
1998-present	American Urological Association (AUA)
1995-present	Medical Society of Virginia
1995-present	Eastern Cooperative Oncology Group (ECOG)
1995-present	American Society for Clinical Oncology (ASCO)
1989-present	American Association for Cancer Research (AACR)
1989-present	Society for Basic Urologic Research (SBUR)
1995-1998	American College of Surgeons (ACS)(Associate Member)
1993-1998	American Urological Association (AUA)(Candidate Member)

**JOURNAL EDITORIAL BOARDS**

---

2004-present	<i>British Journal of Urology-Investigative Section</i>
2004-present	<i>Current Cancer Therapy Reviews</i>
2003	<i>Guest editor: Urologic Clinics of North America: "Followup of GU cancers"</i>
2003-present	<i>BMC Medicine</i>
2003-present	<i>Cancer Letters</i>
2002-present	<i>World Journal of Urology (Research section editor)</i>
2002-present	<i>BMC Cancer</i>
2002-present	<i>BMC Urology</i>
2000-present	<i>Journal of Laparoendoscopic and Advanced Surgical Techniques</i>
2000-present	<i>E-Medicine Textbook of Urology (www.emedicine.com)</i>
2000-present	<i>Prostate Cancer and Prostatic Diseases</i>

**JOURNAL REVIEWER**

---

2003-present	<i>British Journal of Urology</i>
2003-present	<i>Cancer Cell</i>
2002-present	<i>Molecular and Cellular Biology</i>

2002-present	<i>Journal of the National Cancer Institute</i>
2001-present	<i>Cancer Practice</i>
2000-present	<i>Proceedings of National Academy of Science (USA)</i>
2000-present	<i>Nutrition and Cancer</i>
2000-present	<i>Clinical Cancer Research</i>
2000-present	<i>International Journal of Cancer</i>
1998-present	<i>Urologic Oncology</i>
1998-present	<i>Cancer Research</i>
1998-present	<i>Journal of Laparoendoscopic and Advanced Surgical Techniques</i>
1998-present	<i>Urology</i>
1997-present	<i>British Journal of Cancer</i>
1996-present	<i>American Journal of Pathology</i>
1996-present	<i>Clinical Chemistry</i>
1996-present	<i>Cancer</i>
1994-present	<i>Journal of Urology</i>

## EDUCATIONAL HISTORY

---

1994-1995	<i>Clinical Fellow</i> , Urology Service, Memorial Sloan-Kettering Cancer Center, New York, NY.
1991-1994	<i>Resident</i> , Division of Urology, Department of Surgery, University of Toronto, Toronto, Ont.
1988-1991	<i>MRC Research Fellow</i> , Mount Sinai Hospital Research Institute, Faculty of Medicine, University of Toronto, Toronto, Ont.
1986-1987	<i>Surgical Internship</i> , Department of Surgery, University of Toronto, Toronto, Ont.
1982-1986	<i>Medical School</i> , Faculty of Medicine, Queen's University, Kingston, Ont.
1980-1982	<i>Undergraduate Studies</i> , Department of Chemistry, Queen's University, Kingston, Ont.

## HONORS AND AWARDS

---

2004	<i>American Urological Association (AUA) Leadership Program</i>
2002	<i>American Association for Cancer Research (AACR) Sydney Kimmel Award</i>
1999	<i>Resident Teaching Award</i> , Department of Urology, University of Virginia
1998	<i>Paul R. Mellon Chair in Urologic Oncology</i> , Department of Urology, University of Virginia.
1998	<i>Young Investigator Award from the Society for Basic Urologic Research</i>
1998	<i>Edwin Beer Award from the New York Academy of Medicine</i>
1997	<i>Kimmel Foundation Scholar</i>
1996	<i>Recipient of American Cancer Society Career Development Award</i>
1996	<i>Recipient of American College of Surgeons Faculty Research Fellowship</i>
1992	<i>American Urologic Association (N-E and New England Sections) Resident Essay Third Prize</i>
1992	<i>Bard Canada Resident Essay Prize</i> , Division of Urology, University of Toronto.
1991	<i>J.C. Laidlaw Prize</i> (First Place) for Research Excellence, Faculty of Medicine, University of Toronto.
1991	<i>Gallie Bateman Prize</i> (First Place) in Surgical Research, Dept. of Surgery, University of Toronto.
1990	<i>Davis and Geck Resident Essay Prize</i> , Division of Urology, University of Toronto.
1990	<i>Gallie Bateman Prize</i> (Second Place) in Surgical Research, Dept. of Surgery, University of Toronto.
1990	<i>Fellow of the Medical Research Council of Canada</i> .
1990	<i>Canadian Urologic Association Resident Essay Prize</i>
1989	<i>J.C. Laidlaw Prize</i> (Honorable Mention) for Research Excellence, University of Toronto.
1986	<i>Zbar Prize</i> , Faculty of Medicine, Queen's University.
1985	<i>Senator Frank Carell Award</i> for Academic Achievement Faculty of Medicine, Queen's University
1983	<i>Leukemia Research Prize</i> , for Research Excellence from the Canadian Leukemia Research Fund.
1982	<i>Dean's List in the Faculty of Arts and Science</i> , Queen's University.

## NATIONAL AND INTERNATIONAL LECTURES AND PANELS

---

2005 **2005 International Bladder Symposium**, Baltimore, MD  
 Title: "RhoGDI2, a new metastasis suppressor gene in bladder cancer: Discovery and clinical translation"

2004 **Global GU Oncology Conference**, Honolulu, HI  
 Title: "How shall we manage locally advanced prostate cancer? Matched comparison of Brachytherapy and Radical prostatectomy"

2004 **Plenary Session Moderator**: Controversies in Penile Cancer  
 Global GU Oncology Conference, Honolulu, HI.

2004 **83rd Annual Meeting of the Clinical Society of Genitourinary Surgeons**, Charlottesville, VA  
 Title: "RhoGDI2, a new metastasis suppressor gene in bladder cancer: Discovery and clinical translation"

2004 **Baylor University: Department of Urology**, Dallas, TX.  
 Title: "Clinical follow up in urologic oncology"

2004 **Marshfield Clinic: Oncology Center**, Marshfield WI.  
 Title: "The role of RhoGDI2 in human bladder cancer"

2003 **5<sup>th</sup> Society for Urologic Oncology (SUO)**  
 Title: "RhoGDI2: the role and mechanism of action of a new metastasis suppressor gene"

2003 **8<sup>th</sup> Annual Scottsdale Prostate Cancer Conference**, Scottsdale, AZ.  
 Title: "Molecular Staging of Genitourinary Cancers"

2002 **Society for Basic Urologic Research Conference**, Orlando, FL.  
 Title: "Angiogenesis: VEGF in prostate cancer"

2002 **American Association for Cancer Research (AACR)**, San Francisco, CA.  
 Title: "Mechanisms of PTEN mediated cell motility: Role of protein phosphatase activity "

2002 **"Medical College of Virginia 2<sup>nd</sup> Annual Warren Koontz Urology Conference"**, Richmond, VA.  
 Title: "Current Status of Cryotherapy for Genitourinary Cancers"

2002 **"Virginia Urology Center 3<sup>rd</sup> Annual Urology Conference"**, Richmond, VA.  
 Title: "Current Status of Continent Diversions following cystectomy for Bladder Cancer"

2001 **"NIH-Bladder Cancer PRG, Panel Member"**, Washington, DC.  
 Panel: Panel make consensus recommendations for the NIH priorities in bladder cancer research

2001 **"American Brachytherapy Society Consensus Panel Member"**, Nassau, Bahamas.  
 Title: "Current Status of Hormonal therapy in localized Prostate Cancer treated with brachytherapy"  
 Panel: Panel includes 10 members which make consensus recommendations for the ABS

2001 **"Virginia American Cancer Society"**, Fredericksburg, VA.  
 Title: "Current Status of Alternative medicine Use in Prostate Cancer"

2001 **"Medical College of Virginia 1<sup>st</sup> Annual Warren Koontz Urology Conference"**, Richmond, VA.  
 Title: "Current Status of Tumor Markers in Bladder Cancer"

2001 **"Prostate Cancer Update: Kimmel Cancer Center, Philadelphia"**, Philadelphia, PA.  
 Title: "Molecular Regulation of Angiogenesis in Prostate cancer"

2000 **"State of the Science in Superficial Bladder Cancer: NCI Sponsored workshop"**, Washington, DC.  
 Title: "EGF receptor signal transduction in bladder cancer invasion"

2000 **"International Innovators in Urology"**, Dublin, Ireland.  
 Title: "The role of VEGF in prostate cancer metastasis"

2000 **"Department of Urology, Ohio State University "**, Columbus, OH.  
 Title: "Sexual and voiding function and quality of life in prostate cancer"

1999 **"Urology Investigators Forum (UIF) Society"**, New York, NY.  
 Title: "Sexual and voiding function and quality of life in prostate cancer"

1999 **"International Innovators in Urology"**, Cambridge, England.  
 Title: "Quality of life in prostate cancer: Brachytherapy vs. radical surgery"

1999 **Long Island Jewish Medical Center**, New York, NY  
 Title: "Molecular biology of prostate cancer progression: The role of dietary fatty acids"

1998 **"Festschrift for Dr. William Fair, Chair Urology Service Memorial Sloan Kettering, 1984-1997"**  
 New York, NY  
 Title: "Molecular staging of prostate cancer"

1998 ***“International Innovators in Urology”***, London, England.  
Title: “Molecular staging of prostate cancer”

1998 ***“Molecular genetics of bladder cancer: NCI Sponsored workshop”***, Sarasota, FL.  
Title: “EGFR signaling in TCC progression”

1998 ***University of Tennessee***, Knoxville, TN  
Title: “Molecular biology of prostate cancer development: The role of angiogenesis”

1997 ***American Foundation for Urological Disease***, American Urological Association, New Orleans, LA  
Title: “Bladder Health Week 1996: Update and Results”

1997 ***Eastern Cooperative Oncology Group (ECOG) GU Group***, Atlanta, GA  
Title: “Using EGFR inhibitors in the prevention of high grade T1 TCC progression”

1997 ***Moderator, Podium Session on Human Therapeutics***  
Conference: American Cancer Society, Virginia Chapter, Richmond, VA.

1997 ***Maimonides Medical Center***, Brooklyn, NY  
Title: “Molecular biology in staging, prognosis and treatment of prostate cancer”

1996 ***Eastern Cooperative Oncology Group (ECOG) GU Group***, Baltimore, MD  
Title: “The role of p53, bcl-2 and Rb markers in localized prostate cancer progression”

1995 ***Medical College of Virginia***, Richmond, VA  
Title: “The role of p53 in T1 bladder cancer progression”

1992 ***Department of Urology, M.D. Anderson Hospital and Tumor Institute***, Houston, TX.  
Title: “Ha-ras and EGF-R expression in transitional cell carcinoma growth and invasion”

1992 ***Fourth International Congress of The Metastasis Research Society***, Paris, France.  
Title: “Suppression of TGF-beta1 secretion enhances the aggressiveness of colon cancer”

1991 ***Co-Chairperson, Poster Discussion Session on Biology of Metastasis***  
Conference: American Association for Cancer Research, Houston, Texas.

1990 ***International Molecular Genetics of Bladder Cancer Meeting***, Prouts Neck, MA  
Title: “Ha-ras and EGF-R expression in transitional cell carcinoma growth and invasion”

---

## PROFESSIONAL SOCIETY PROGRAMS

---

2005 ***Plenary Session Pannelist: Controversies in Superficial Bladder Cancer***  
American Urological Association, San Antonio, TX.

2005 ***Postgraduate Course in Urologic Oncology***, American Urological Association, San Antonio, TX.  
Title: “Clinical follow up in urologic oncology”  
Participants: Dr. S. Machele Donat (director)

2005 ***Program Committee: Bladder Cancer***  
Conference: American Urological Association, San Antonio, TX.

2004 ***Instructor, AUA-Basic Science for Urologists Course***  
Title: “Basic molecular biology for urologists”  
Conference: American Urological Association (AUA) Sponsored course, Charlottesville, VA.

2004 ***Co-Moderator, Poster Discussion Session: Bladder Cancer Research I***  
Conference: American Urological Association, San Francisco, CA

2004 ***Program Committee: Bladder Cancer***  
Conference: American Urological Association, San Francisco, CA.

2004 ***Postgraduate Course in Urologic Oncology***, American Urological Association, San Francisco, CA.  
Title: “Clinical follow up in urologic oncology”  
Participants: Dr. S. Machele Donat (director)

2004 ***Co-Moderator, Metastasis Podium Session***  
Conference: American Association for Cancer Research (AACR), Orlando, FL.

2003 ***Moderator, Plenary Session: Molecular therapeutics***  
Conference: Society for Urologic Oncology (SUO), Bethesda, MD.

2003 ***Instructor, AUA-Basic Science for Urologists Course***  
Title: “Basic molecular biology for urologists”  
Conference: American Urological Association Sponsored course, Charlottesville, VA.

2003 **Co-Moderator, Poster Discussion Session: Bladder Cancer Research II**  
 Conference: American Urological Association, Chicago, IL.

2003 **Postgraduate Course in Urologic Oncology**, American Urological Association, Chicago, IL  
 Title: "Clinical follow up in urologic oncology"  
 Participants: Dr. S. Machele Donat (director)

2002 **Program Committee: Bladder Cancer Sessions**  
 Conference: American Urological Association, Chicago, IL.

2002 **Plenary Session Summary: Highlights of Prostate Cancer Sessions**  
 Conference: Société Internationale d'Urologie (SIU), Stockholm.

2002 **Co-Moderator, Podium Session on Prostate Cancer**  
 Conference: American Urological Association-Mid Atlantic Section, Baltimore, MD.

2002 **Instructor, AUA-Basic Science for Urologists Course**  
 Title: "Basic molecular biology for urologists"  
 Conference: American Urological Association Sponsored course, Charlottesville, VA.

2002 **Plenary Session Summary: Highlights of Bladder Cancer Sessions**  
 Conference: American Urological Association, Orlando, FL.

2002 **Program Committee: Abstract review team (bladder cancer)**  
 Conference: American Urological Association, Orlando, FL.

2001 **Co-Moderator, Podium Session on Advanced Bladder Cancer**  
 Conference: American Urological Association, Anaheim, CA.

2000 **Plenary Session Lecture**  
 Title: "Penile Cancer: Diagnosis and Staging"  
 Conference: Société Internationale d'Urologie (SIU), Singapore.

2000 **Moderator, Kidney Cancer Poster Session**  
 Conference: Société Internationale d'Urologie (SIU)", Singapore.

2000 **Chairman, Scientific Program Committee**  
 Conference: American Urological Association-Mid Atlantic Section, Puerto Rico.

1999 **Member, Scientific Program Committee**  
 Conference: American Urological Association-Mid Atlantic Section, Hilton Head, NC

1999 **Postgraduate Course in Urologic Oncology**, American Urological Association, Dallas, TX  
 Title: "Clinical follow up in urologic oncology"  
 Participants: Drs. William Fair (director), Michele Donat and Guido Dalbagni

1998 **Resident Essay Prize Selection Committee**  
 Conference: American Urological Association-Mid Atlantic Section, Palm Beach, FL.

1998 **Co-Moderator, Podium Session on Prostate Cancer**  
 Conference: American Urological Association-Mid Atlantic Section, Palm Beach, FL.

1998 **Virginia Urological Society Annual Meeting**, Virginia Urological Society, Charlottesville, VA  
 Title: "Continent diversions in women: Pearls and pitfalls"

1998 **Postgraduate Course in Urologic Oncology**, American Urological Association, San Diego, CA  
 Title: "Clinical follow up in urologic oncology"  
 Participants: Drs. William Fair (director), Michele Donat and Guido Dalbagni

1996 **Virginia Urological Society Annual Meeting**, Virginia Urological Society, Richmond, VA  
 Title: "The role of molecular markers in bladder cancer progression",

## CME COURSES AND SYMPOSIA

---

2003 **"Richmond Urologic Forum"**, Richmond, VA.  
*Lecture 1 Title:* "Current Status of Continent Diversions following cystectomy for Bladder Cancer"  
*Lecture 2 Title:* "Clinical follow up in urologic oncology"

2001 **Third Annual Mid Atlantic Urology Seminar**, Banff, Alberta  
 Title: "Second opinion pathologic review in bladder cancer: Costs and benefits"

2000 **"Management of Prostate Cancer in the Year 2000"**, Atlanta, GA  
 Title: "Quality of life following treatment of localized prostate cancer"

2000 **"20<sup>th</sup> Annual Jackson Hole Urology Conference"**, Jackson Hole, WY  
Title: "Molecular prognostic factors in prostate cancer"

1999 **Second Annual Mid Atlantic Urology Seminar**, Taos, NM  
Title: "Molecular staging of prostate cancer"

1998 **Virginia Beach Cancer Center**, Virginia Beach, VA  
Title: "Molecular biology in staging, prognosis and treatment of prostate cancer"

1998 **Department of Surgery Grand Rounds, University of Virginia**, Charlottesville, VA  
Title: "The emerging role of brachytherapy in the treatment of localized prostate cancer"

1998 **First Annual Mid Atlantic Urology Seminar**, Montreal, Quebec  
Title: "Partial nephrectomy: Emerging role in management of renal cell cancer"

1997 **36th Annual Medical Staff Oncology Seminar**, Halifax Regional Hospital, South Boston, VA  
Title: "New advances in prostate cancer brachytherapy"

1997 **Day at Virginia, University of Virginia**, Charlottesville, VA  
Title: "The role of lymphadenectomy in the treatment of penile cancer"

1997 **Prostate Brachytherapy Course, University of Virginia**, Charlottesville, VA  
Title: "The use of chemosensitizers in prostate cancer radiotherapy"  
Note: Two day course every two months

1995 **Course in Prostate Oncology, Rockingham Memorial Hospital**, Harrisonburg, VA  
Title: "Prostate specific antigen (PSA): New advances"

1995 **Day at Virginia, University of Virginia**, Charlottesville, VA  
Title: "Partial nephrectomy: Who ? Why ? and How ?"

1995 **Course in Surgical Oncology, University of Virginia**, Charlottesville, VA  
Title: "Novel treatments of localized prostate cancer"

---

## STRUCTURED TEACHING

1993 Third Year medical students (St. Michael's Hospital, University of Toronto, Toronto, Ont.)  
Time: 2hrs/week x 12 weeks  
Topic: General Urology

1995-present Department: Urology  
Level: Third year medical students  
Time: 1 hr/month  
Topic: Bladder Cancer

1997-2002 Department: Molecular Physiology and Biological Physics (Physiology 852)  
Course/Level: Graduate students  
Time: 1.5 hr/6 months  
Topic: Tumor Angiogenesis

1999-2002 Department: Microbiology (Molecular Basis of Cancer)  
Level: Graduate students  
Time: 2 hr/6 months  
Topic: Tumor Angiogenesis

---

## TRAINING GRANT FACULTY

Principal Investigator:  
Project Number:  
Source:

**Sarah J. Parsons**  
5T32CA09109-24  
National Cancer Institute

Last Update: Tuesday, February 08, 2005

Title of Project: Cancer Research Training In Molecular Biology

Principal Investigator: **Brian Duling**  
Project Number: 5T32HL07284-23

Source: National Heart, Lung, And Blood Institute  
Title of Project: Basic Cardiovascular Research Training Grant

Principal Investigator: **Gary Owens**  
Project Number: N/A  
Source: NIH  
Title of Project: MD/PhD Training Grant

Principal Investigator: **Michael Weber**  
Title of Project: Molecular Medicine program

## **UNDERGRADUATE AND MEDICAL STUDENTS**

---

1997 summer John Tiedman (summer research student)  
1997-1998 Michael Emmanuel Herce (mentor for Biology 495-496 Research Project)  
1998 summer Sayeh Farivar (NIH summer undergraduate research student)  
1999 summer Anna Jackson (NIH summer undergraduate research student)  
2000 summer Chris Geiger (NIH summer undergraduate research student)  
2000 summer Lex Thomas (UVA Cancer Center medical student)  
2001 summer Joshua Hall (NIH Alternative Medicine Center medical student)

## **GRADUATE STUDENTS**

---

1996-2000 Amy Ma (member of PhD thesis committee: Department of Microbiology)  
1997-2002 Paul D. Deeble (member of PhD thesis committee: Department of Microbiology)  
1998-2002 Robert E. Bakin (member of PhD thesis committee: Department of Microbiology)  
2001-2004 Brian E. Nicholson (PhD supervisor: Department of Molecular Physiology)  
2004-present Steven Smith (PhD supervisor: Department of Molecular Physiology)  
2004-present David Chernauskas (PhD supervisor: Department of Molecular Physiology)  
2004-present Rooshin Dalal (member of PhD thesis committee: Department of Cell Biology)

## **RESIDENTS AND CLINICAL RESEARCH FELLOWS**

---

1995-1996 Stanford Broder MD (urology resident doing clinical research). *Dr. Broder has been the recipient of the 3rd prize for clinical research at the 1997 American Urological Association meeting for his contribution to publication #25)*  
1996-1997 Emin Ozbek MD (clinical urology research fellow)  
1996-1997 Christopher Crane (radiation oncology resident doing clinical research)  
1998-1999 Tracy Krupsky MD (urology resident doing basic and clinical research) *Dr. Krupski has been the recipient of the University of Virginia School of Medicine Resident prize for research for 2000, for her contribution to publication #43)*  
1998-2000 Brant Fulmer MD (urology resident doing clinical research)  
1999-2001 Terrance Chapman MD (urology resident doing clinical research)  
2000-2003 Timothy Coblenz MD (urology resident doing clinical research) *Dr. Coblenz has been the recipient of the 1st prize for clinical research at the 2000 Mid-Atlantic American Urological Association meeting for his contribution to publication #51)*  
2000-2004 Emily Smith MD (urology resident doing clinical research)

2001-2005	Nicole Miller MD (urology resident doing clinical research) <i>Dr. Miller has been the recipient of the 1st prize for clinical research at the 2004 Mid-Atlantic American Urological Association meeting for her contribution to publication #51)</i>
2001-2005	Antoine Maklouf MD PhD (urology resident doing clinical research)
2002-present	Jeff Woolsey MD (urology resident doing clinical research)
2003-present	Hillary Copp MD (urology resident doing clinical research)
2003-present	Sophie Fletcher MD (urology resident doing clinical research)
2004-present	Sarah Coleman MD (urology resident doing clinical research)

## **POSTDOCTORAL FELLOWS**

---

1995-1996	François LeGal PhD (postdoctoral supervisor)
1997-present	Michael Harding PhD (postdoctoral supervisor) <i>Dr. Harding is the recipient of an NIH Training Grant, 1997-2000) and the recipient of the Pfizer Scholar in Urology Award for Urological research in 1999.</i>
1998-2002	John Gildea PhD (postdoctoral supervisor) <i>Dr. Gildea is the recipient of an American Foundation of Urologic Disease AFUD fellowship, 1999-2002</i>
1998-2001	Essam Sheta PhD (postdoctoral supervisor) <i>Dr. Sheta is the recipient of an NIH Training Grant, 1999-2001</i>
1999-2002	Jabed Seraj MD PhD (postdoctoral supervisor) <i>Dr. Seraj is the recipient of an NIH Training Grant, 2000-2001</i>
2001-present	Dora Bigler PhD (postdoctoral supervisor)
2001-present	Gary Oxford PhD (postdoctoral supervisor) <i>Dr. Oxford is the recipient of an NIH Training Grant, 2002-2005</i>
2001-present	Mikel Herlevsen PhD (postdoctoral supervisor)
2002-present	Brian Titus PhD (postdoctoral supervisor) <i>Dr. Titus is the recipient of an American Foundation of Urologic Disease AFUD fellowship, 2003-2005</i>
2002-present	Zhong Wu PhD (postdoctoral supervisor)
2003-present	Tonia Foreman PhD (postdoctoral supervisor)
2005-present	Yimin Wu PhD (postdoctoral supervisor)

## **PEER REVIEWED GRANT STUDY SECTIONS**

---

1998-present	<b>American Cancer Society</b> <i>Study Section: IRG</i> <i>Site: University of Virginia, Charlottesville, VA</i>
1998-2000	<b>U.S. Army Prostate Cancer Research Program</b> <i>Study Section: Cell and Molecular Biology #2</i> <i>1998: Study Section Secretary: Dr. Harold Waters</i> <i>1999: Study Section Secretary: Dr. Dolores Lowry</i> <i>2000: Study Section Secretary: Dr. Dolores Lowry</i>
2004-2009	<b>American Cancer Society</b> <i>Study Section: Cell Structure and Metastasis</i> <i>SRA: Christopher Widnell</i> <i>Site: American Cancer Society, Atlanta, GA</i>

**PAST MAJOR PRIOR PEER REVIEWED GRANTS**

---

Principal Investigator: Dan Theodorescu  
 Project Number: 9599  
 Source: **American Cancer Society**  
 Title of Project: Molecular genetics of prostate cancer progression  
 Dates of Approved/Proposed Project: 7/1/96-6/30/99

Principal Investigator: Dan Theodorescu  
 Project Number: 3476 (grant based in ACS CDA 9599 obtained 7/96)  
 Source: **American Cancer Society**  
 Title of Project: Molecular genetics of prostate cancer metastasis  
 Dates of Approved/Proposed Project: 7/1/00-1/30/03

Principal Investigator: Dan Theodorescu  
 Project Number: R29-CA75115 (renewed with R01-CA75115)  
 Source: **National Cancer Institute**  
 Title of Project: Molecular genetics of bladder cancer progression  
 Dates of Approved/Proposed Project: 9/1/97-8/30/02

**CURRENT MAJOR PEER REVIEWED GRANTS**

---

Principal Investigator: Dan Theodorescu  
 Active/Pending Active  
 Project Number: R01-CA75115 (renewal of grant obtained 9/97)  
 Source: **National Cancer Institute**  
 Title of Project: Molecular genetics of bladder cancer progression  
 Dates of Approved/Proposed Project: 2/1/03-1/30/08

Principal Investigator: Dan Theodorescu  
 Active/Pending Active  
 Project Number: R01-CA58123  
 Source: **National Cancer Institute**  
 Title of Project: Molecular regulation of VEGF in prostate cancer  
 Dates of Approved/Proposed Project: 7/1/01-6/30/06

Principal Investigator: Dan Theodorescu  
 Active/Pending Pending  
 Project Number: Program Project (patent committee score of 128 from 12/29/04)  
 Source: **National Cancer Institute**  
 Title of Project: Signal Transduction in Prostate Cancer progression  
 Dates of Approved/Proposed Project: 8/1/05-7/30/10

**CLINICAL TRIALS**

---

*Sponsor:* **University of Virginia**  
*Investigators:* Drs. Santen, Myers, Theodorescu, Fisch  
*Trial:* Arimidex, a new second line agent for hormonally refractory prostate cancer  
*Status:* Completed

*Sponsor:* **Jenssen Pharmaceuticals**  
*Investigators:* 6 teaching institutions in the US.  
*Trial:* The use of a novel oral Farnesyl Transferase Inhibitor in the treatment of BCG refractory bladder cancer.

*Status:* Completed

*Sponsor:* **Bard Diagnostic Sciences Inc.**

*Investigators:* National

*Trial:* Determining the utility of the BTA assay in establishing cost effective ways to monitor patients with past history of superficial bladder cancer.

*Status:* Completed

*Sponsor:* **University of Virginia**

*Investigators:* Drs. Theodorescu, Thomas

*Trial:* Ketoconazole-Taxotere for hormone refractory prostate cancer: Phase I with molecular correlates

*Status:* Application to IRB ongoing

## **PUBLICATIONS (Indexed)**

---

1. **Blair, G.K., Filler, R.M., and Theodorescu, D.** 1987. Neonatal pharyngoesophageal perforation mimicking esophageal atresia: clues to diagnosis. *J Pediatr Surg*, 22: 770-774
2. **Adams, C., Theodorescu, D., Murphy, E.G., and Shandling, B.** 1990. Thymectomy in juvenile myasthenia gravis. *J Child Neurol*, 5: 215-218
3. **Theodorescu, D., Cornil, I., Fernandez, B.J., and Kerbel, R.S.** 1990. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. *Proc Natl Acad Sci U S A*, 87: 9047-9051
4. **Cornil, I., Theodorescu, D., Man, S., Herlyn, M., Jambrosic, J., and Kerbel, R.S.** 1991. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. *Proc Natl Acad Sci U S A*, 88: 6028-6032
5. **Cornil, I., Theodorescu, D., Kerbel, R.S., and Poupon, M.F.** 1991. Metastatic dissemination of cancer cells. *Pathol Biol (Paris)*, 39: 300-307
6. **Fu, X.Y., Theodorescu, D., Kerbel, R.S., and Hoffman, R.M.** 1991. Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. *Int J Cancer*, 49: 938-939
7. **Kerbel, R.S., Cornil, I., and Theodorescu, D.** 1991. Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. *Cancer Metastasis Rev*, 10: 201-215
8. **Theodorescu, D., Caltabiano, M., Greig, R., Rieman, D., and Kerbel, R.S.** 1991. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo. *J Cell Physiol*, 148: 380-390
9. **Theodorescu, D., Cornil, I., Sheehan, C., Man, S., and Kerbel, R.S.** 1991. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. *Int J Cancer*, 47: 118-123
10. **Theodorescu, D., Cornil, I., Sheehan, C., Man, M.S., and Kerbel, R.S.** 1991. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. *Cancer Res*, 51: 4486-4491

11. Theodorescu, D., Bergsma, D., Man, M.S., Elshourbagy, N., Sheehan, C., Rieman, D., and Kerbel, R.S. 1991. Cloning and overexpression of TGF-beta 1 cDNA in a mammary adenocarcinoma: in vitro and in vivo effects. *Growth Factors*, 5: 305-316
12. Theodorescu, D., Witchell, S., and Connolly, J. 1991. Chronic adult renal vein thrombosis: two unusual cases and a review of the literature. *Int Urol Nephrol*, 23: 429-435
13. Theodorescu, D., Binnington, A.G., and Connolly, J.G. 1992. The intestinoprostatic capsule anastomosis: functional and anatomic results in a canine model. *Can J Surg*, 35: 169-172
14. Wu\*, S.P., Theodorescu, D\*, Kerbel, R.S., Willson, J.K., Mulder, K.M., Humphrey, L.E., and Brattain, M.G. 1992. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. *J Cell Biol*, 116: 187-196.\*(equal first authors)
15. Schuh, A.C., Theodorescu, D., Shalaby, F., and Breitman, M.L. 1993. Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis. *Cell Growth Differ*, 4: 177-184
16. Theodorescu, D., Connors, K.M., Groce, A., Hoffman, R.M., and Kerbel, R.S. 1993. Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. *Anticancer Res*, 13: 941-946
17. Theodorescu, D., Sheehan, C., and Kerbel, R.S. 1993. TGF-beta gene expression depends on tissue architecture. *In Vitro Cell Dev Biol*, 29A: 105-108
18. Huang, F., Newman, E., Theodorescu, D., Kerbel, R.S., and Friedman, E. 1995. Transforming growth factor beta-1 (tgf-beta-1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a tgf-beta-1 antisense expression plasmid. *Cell Growth Differ*, 6:1635-1642
19. Theodorescu, D. 1996. Genetic prognostic markers for transitional cell carcinoma of the bladder: From microscopes to molecules. *J. Urol.* 155(1):2
20. Theodorescu, D., Russo, P., Zhang, Z.F., Morash, C., and Fair, W.R. 1996. Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. *J Urol* 155(5):1626-1631
21. Theodorescu, D. 1996. Prostate Cancer - Our Patients' Questions. *J. Urol.* 155(5):1661-1662
22. Frierson, H. W., Theodorescu, D., and Hannigan, M.C. 1997. Clinicopathological study of gamma-glutamyl transferase (GGT) in benign and malignant prostate. *Mod Pathol* 10(1):1-6.
23. Lajvardi, A., Theodorescu, D., and Older R.O. 1997. A mullerian duct cyst presenting as a complex pelvic mass. *J. Urol.* 157(3):958.
24. Herrel, D., Trachtenberg, J. and Theodorescu, D. 1997. Pelvic lymphadenectomy in prostate cancer: comparison of three surgical techniques. *J. Urol.* 157(4):1337-1339.
25. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E. and Frierson, H. W. 1997. The use of p53, bcl-2 and Rb protein expression as prognostic markers in localized carcinoma of the prostate. *J. Urol.* 158(1):131-137.
26. Theodorescu, D. 1997. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance - Comment. *J. Urol* 157(5):1709

27. **Harding M. and Theodorescu, D.** 1997 Molecular biology: its role as a prognostic indicator for bladder cancer. *Current Opinion in Urology* 7: 282-286
28. **Lippert, M. C. and Theodorescu, D.** 1997 The Hautmann neobladder with a chimney: a versatile modification. *J Urol* 158 (4): 1510-1512
29. **Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E., and Frierson, H. F., Jr.** 1997 Chromogranin A as a long-term prognostic markers in localized carcinoma of the prostate. *Cancer* 80 (11): 2109-2119
30. **Theodorescu, D., Lippert, M. C., Broder, S. R., and Boyd, J. C.** 1998 Early PSA failure following radical prostatectomy: The importance of surgical technique. *Urology* 51 (2): 277-282
31. **Theodorescu, D., Balcom, A., Churchill, B.M., and Khoury, A. E.** 1998 Urethral replacement with vascularized tunica vaginalis: defining optimal form of use. *J Urol* 159 (5):1708-1711
32. **Theodorescu, D.** 1998 Correlation between p53 over expression and response to bacillus calmette-guerin therapy in a high risk select population of patients with T1G3 bladder cancer - Comment. *J Urol* 159 (3):791
33. **Theodorescu, D., Laderoute K. R., Calaoagan J. M. and Gulding, K. M.** 1998 Inhibition of human bladder cancer motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. *Int J Cancer* 78(6):775-782
34. **Crane C. H., Clark M., Petroni G., and Theodorescu, D.** 1998 The Bladder Tumor Antigen (BTA) test: performance in patients undergoing pelvic irradiation for non bladder malignancies. *Int J Radiat Oncol Biol Phys* 43(1):73-77
35. **Theodorescu, D., Laderoute, K. R., and Gulding, K. M.** 1998 Epidermal growth factor receptor regulated human bladder cancer motility is a phosphatidylinositol 3-kinase mediated process. *Cell Growth Differ* 9(11):919-928
36. **Theodorescu, D., Frierson, H. W. and Sikes R. A.** 1999 Molecular analysis of surgical margins following radical prostatectomy for localized prostate cancer. *J Urol* 161(5):1442-1448
37. **Gray, M., Petroni G. and Theodorescu, D.** 1999. Urinary function following radical prostatectomy: comparison of retropubic and perineal techniques. *Urology* 53(5):881-890
38. **Harding M. and Theodorescu, D.** 1999 Prognostic markers for adenocarcinoma of the prostate: From microscopes to molecules. *Cancer and Metastasis Reviews* 17(4):429-37
39. **Broder, S. R., Frierson, H. W. and Theodorescu, D.** 1999 Unusual case of non exophytic invasive penile squamous cancer arising from a chronic sinus tract. *Scandinavian Journal of Urology & Nephrology* 33(5):333-35
40. **Lippert, M. C., McClain, R., Boyd, J. C. and Theodorescu, D.** 1999 Alternative Medicine Use in Patients Treated With Curative Intent for Localized Prostate Cancer. *Cancer* 86(12):2642-2648
41. **Gildea, J. J., Golden, W., Harding, M. A., and Theodorescu D.** 2000 The phenotypic and cytogenetic analysis of T24T, a highly tumorigenic subline of the human bladder cancer cell line t24. *Genes Chromosomes and Cancer* 27(3):252-63
42. **Krupsky, T., Frierson, H. W., Petroni G., and Theodorescu, D.** 2000 P53, Rb proteins and area weighted microvessel density are long term survival markers in localized carcinoma of the prostate. *Urology* 55(5):743-9

43. Krupsky, T., Bissonette, E., Petroni, G., Theodorescu, D. 2000 Comparison of quality of life in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *Urology* 55(5):736-42

44. Sheta, E. A., Harding, M. A., and Theodorescu, D. 2000 Vascular endothelial growth factor is transcriptionally regulated by cell density in prostate cancer cells. *J Natl Cancer Inst* 92(13):1065-73

45. Im, D, Heise, C. E. A., Harding, M. A., O'Dowd, B. F., Theodorescu, D., and Lynch, K. R. 2000 Molecular cloning and characterization of a lysophosphatidic acid receptor, EDG-7, expressed in prostate. *Mol Pharmacol* 57(4):753-9

46. Krupsky, T., Moskaluk, C.A., Boyd, J. C. and Theodorescu, D. 2000 Classical markers and area weighted microvessel density in the prediction of clinical stage of carcinoma of the bladder. *Br J Urol* 85(9):1027-32

47. Gildea, J. J., Harding, M. A., and Theodorescu D. 2000 A novel and quantitative assay to measure genetic and pharmacologic effects on tumor cell motility and invasion. *BioTechniques* 29:81-86

48. Gardner, T. A., Bissonette, E., Petroni, G., Sokoloff, M., McClain, R., and Theodorescu, D., 2000 Operative and postoperative factors affecting length of stay following radical prostatectomy. *Cancer* 89: 424-430

49. Theodorescu, D., Gillenwater, J.Y., and Koutrouvelis, P.G. 2000. Prostatourethral-rectal fistula formation following prostate brachytherapy: incidence and risk factors. *Cancer* 89: 2085-2091

50. Sheta, E. A., Harding, M. A., and Theodorescu, D. 2001. Normoxic induction of active HIF-1 $\alpha$  protein by cell density is dependent on Nitric Oxide and Ras / MAP Kinase mediated signaling pathways. *Oncogene*. 20(52):7624-34

51. Coblenz, T., Mills, S. E. and Theodorescu, D., 2001. The value of second opinion pathology in the evaluation of patients referred for radical cystectomy. *Cancer*. 91(7):1284-90

52. Fulmer, B., Petroni G, and Theodorescu, D. 2001. Prospective comparison of sexual and voiding function in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *Cancer*. 91(11):2046-55

53. Krupsky, T., Harding, M. A., and Theodorescu, D. 2001. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. *Growth Factors* 18: 287-302

54. Seraj, M. J., Gildea, J. J., Harding, M. A., and Theodorescu, D. 2001. Molecular determination of perivesical and lymph node metastasis following radical cystectomy for urothelial carcinoma of the bladder. *Clinical Cancer research* 7: 1516-1522

55. Seraj, M. J., Gildea, J. J., Harding, M. A., and Theodorescu, D. 2001. Metastatic potential and metastasis related gene expression of lineage related human bladder cancer cell lines. *Clinical and Experimental Metastasis* 18: 519-525

56. Fulmer, B., Petroni G, and Theodorescu, D. 2001. PSA velocity at tumor recurrence following radical prostatectomy: a surrogate marker for increased tumor aggressiveness in African American men. *J Urol* 166:1328-1331

57. Smith, E. and Theodorescu, D. 2001. Evaluation of urinary continence and voiding function: Early results in men with the neourethral modification of the Hautmann orthotopic neobladder. *J Urol* 166: 1346-1349

58. Santen, R. J., Fisch, M., Myers, C., Theodorescu, D., Petroni, G., and Cohen, R. 2001. Use of the Aromatase Inhibitor Anastrozole in the Treatment of Advanced Prostate Cancer. *Cancer* 92: 2095-2101

59. **Theodorescu, D., Sorensen, E. J. and Older R.O.** 2001 Metastatic melanoma presenting as an ileal conduit filling defect *J. Urol* 166: 1393-1394

60. **Chen, C., Frierson, H. F., Haggerty, P. F., Theodorescu, D., Gregory, C. W., Dong, J.T.** 2001. An 800 kb Region of Deletion at 13q14 in Human Prostate and Other Carcinomas. *Genomics* 77: 135-144

61. **Nicholson B, Schaefer G, Theodorescu D.** 2001. Angiogenesis in prostate cancer: biology and therapeutic opportunities. *Cancer Metastasis Rev.* 20(3-4):297-319

62. **Gildea, J. J., and Theodorescu D.** 2002. The Role of Ral A in Epidermal Growth Factor Receptor-regulated Cell Motility. *Cancer Research* 62: 982-985.

63. **Karns, L.R., Kisielewski, A., Gulding, K.M., and Theodorescu, D.** 2002. Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. *BMC Biotechnol* 1: 11

64. **Smith, E. Frierson, H. F., Mills, S. E., and Theodorescu, D.** 2002. Gleason scores of prostate biopsy and radical prostatectomy specimens over a 10 period: Is there any evidence for systematic upgrading? *Cancer*. 94, 2282-7

65. **Chesson, J. and Theodorescu, D.** 2002 Adrenal tumor with caval extension: case report and review of the literature. *Scandinavian Journal of Urology & Nephrology* 36, 71-3

66. **Coblentz, T., Bissonette, E., Petroni, G., and Theodorescu, D.,** 2002. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: Early results in high risk patients. *Prostate Cancer and Prostate Diseases* 5(3):219-25

67. **Coblentz, T. and Theodorescu, D.,** 2002. Modified inguinal lymphadenectomy in the management of high risk penile cancer. *J. Urol* 168(4 Pt 1):1386-9

68. **Maklouf, A., Bissonette, E., and Theodorescu, D.,** 2002. Comparison of the costs and charges associated with multimodality radiotherapy and radical prostatectomy in the treatment of clinically localized prostate cancer: *Urol* 60(4):656-60

69. **Theodorescu, D.** 2003. Invited review: Molecular Pathogenesis of Proliferative and Progressive Urothelial Cancer. *Histol Histopathol* 18: 259-274

70. **Valicenti, R. K., Bissonette, E., Petroni, G., and Theodorescu, D.** 2003. Comparison of Sexual Function and Satisfaction Between 3D Conformal Radiation Therapy and Transperineal Prostate Brachytherapy. *J. Urol* 168(6):2499-504

71. **Oxford, G. K., and Theodorescu, D.** 2003. Invited Review: Small G proteins in cancer cell motility and invasion. *Cancer Letters* 189(2):117-28

72. **Harding, M. A., Gildea, J. J., and Theodorescu D.** 2002 Functional Genomic Comparison of Lineage Related Human Bladder Cancer Cell Lines with Differing Tumorigenic and Metastatic Potentials by SKY, CGH and a novel method of Positional Expression Profiling. *Cancer Research* 62(23):6981-9

73. **Hall, J.D., Boyd, J.C., and Theodorescu D.** 2003. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive pilot survey. *Urology* 61: 402-407

74. **Miller, N. Bissonette, E., and Theodorescu, D.** 2003. The impact of a novel neoadjuvant hormonal therapy on the quality of life of patients treated by brachytherapy for clinically localized prostate cancer? *Cancer* 97: 1203-1210

77. Krupski, T., Bissonette, E., Theodorescu, D. 2003. Impact of prostate volume on voiding function and quality of life in patients treated by brachytherapy for clinically localized prostate cancer. *European Urology* 43: 467-472, 2003

78. Bigler, D. and Theodorescu, D. 2003 A novel approach to understanding the effects of botanical extracts on human prostate cancer. *Oncogene* 22: 1261-1272

79. Hall, J., Bissonette, E., Theodorescu, D. 2003. Motivations for use of complementary medicine in patients with localized prostate cancer treated with curative intent. *British J. Urol* 91: 603-607

80. Nicholson, B. and Theodorescu, D. Molecular therapeutics in prostate cancer. *Histol Histopathol*, 18: 275-298, 2003.

75. Gildea, J. J., Harding, M, A., and Theodorescu D. 2002. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. *Cancer Research* 62(22):6418-23

81. Woolsey, J., Miller, N., and Theodorescu, D. 2003 Permanent interstitial brachytherapy for prostate cancer: a current review. *World J Urol*, 21: 209-219.

82. Theodorescu, D. Molecular pathogenesis of urothelial bladder cancer. *Histol Histopathol*, 18: 259-274, 2003.

83. Theodorescu, D. Phosphoinositide signaling in urological disease. *J Urol*, 169: 2394-2396, 2003.

84. Oxford, G. and Theodorescu, D. 2003. The role of Ras superfamily proteins in bladder cancer progression. *J Urol*, 170: 1987-1993

85. Horwitz, E.M., Miller, N., Uzzo, R.G., and Theodorescu, D. 2003. Brachytherapy for prostate cancer: follow-up and management of treatment failures. *Urologic Clinics of North America* 30: 737-750

86. Nicholson, B. and Theodorescu, D. 2004 Angiogenesis and prostate cancer tumor growth. *J Cell Biochem*, 91: 125-150,

87. Bassignani MJ, Moore Y, Watson L. and Theodorescu, D. 2004. Pilot Experience with Real-Time Ultrasound Guided Percutaneous Renal Mass Cryoablation *J. Urol* 171(4):1620-3

88. Maklouf, A., Krupski, T.A., Bissonette, E., and Theodorescu, D. 2004. The impact of increased number of sampled cores on the predictive accuracy of pathological grade and tumor distribution in the prostate biopsy. *British J. Urol* 93(3):271-4

89. Ames C.D., Frierson, H.F., and Theodorescu D. 2004. Unusual case of recurrent low grade invasive and endophytic squamous cell carcinoma of the penis. *Scand J Urol Nephrol*, 38:3, 258-259.

90. Miller, N., and Theodorescu, D. 2004. Quality of Life in Brachytherapy for Prostate Cancer: A Current Review. *British J. Urol* 94(4):487-91

91. Gildea, J. J., Chen, C, Dong, J-T., and Theodorescu D. 2004. Suppression of motility of a human bladder cancer cell line by wild type PTEN/MMAC is dependent on its protein phosphatase activity. *Oncogene* 23(40):6788-97

92. Theodorescu D, Gildea, J. J., Harding, M, A., Conaway, M., and Frierson, H.F. 2004. Reduced expression of metastasis suppressor rhogd2 is associated with decreased survival for patients with bladder cancer. *Clinical Cancer Research* 10(11):3800-6

93. **Theodorescu D and Frierson, H.F.** 2004. When is a negative node really negative: The relevance of molecular tools in the detection of lymph node metastasis. *Urologic Oncology* 22(3):256-9
94. **Bradley E, Bissonette, E., and Theodorescu, D.** 2004. Determinants of long term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer *British J. Urol* 94: 1003-1009
95. **Nicholson, B., Harding, M, A., Conaway, M., Frierson, H.F. and Theodorescu D.** 2004. Mapping the evolution of human metastatic bladder cancer. *Cancer Research* 64: 7813-7821
96. **Koutrouvelis, P.G., Theodorescu, D., Katz, S., Lailas, N., Hendricks, F.** 2004. Brachytherapy of Prostate Cancer after Colectomy for Colorectal Cancer: Pilot experience *J. Urol* 173: 82-85; discussion 85-86
97. **Woolsey, J., Bissonette, E., Schneider, B., and Theodorescu, D.** 2004. Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: a single center report. *J Urol* 172: 2528-2531
98. **Copp, H., Bissonette, E., and Theodorescu, D.,** 2004. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer in high risk patients. *Urology* (in press)
99. **Miller, N. Bissonette, E., and Theodorescu, D.** 2004. Undetectable PSA at 6-12 months: a new marker for early success in hormonally treated patients following prostate brachytherapy *Cancer* (in press)
100. **Globus, T., Theodorescu, D., Frierson, H.F. Woolard, D.** 2005. Terahertz spectroscopic characterization of cancer cells. *SPIE Proceedings*, Vol. 5692. (in press)
101. **Fletcher, S., and Theodorescu D.** 2005. What is the best treatment for advanced prostate cancer: Surgery or radiation? *Can J Urol* (in press)
102. **Theodorescu, D., Fliser, D., Wittke, S., Mischak, H.** 2005. Pilot study of capillary electrophoresis coupled to mass spectrometry as tool to define potential prostate cancer biomarkers in urine. *Electrophoresis*. (in press)

---

## PHD THESIS

**Theodorescu, D.** 1993. Mechanisms of epithelial tumor growth and metastasis: a role for transforming growth factor  $\beta$ . *National Library of Canada. Thesis (Ph.D.)*-University of Toronto, ISBN: 0315828560

---

## SERIES EDITOR

1. **Theodorescu, D.** 2003. Followup in Urological Cancer. *Urologic Clinics of North America*, Volume 30
2. **Theodorescu, D. and Pollack, A.** 2003. Radiation Therapy for prostate cancer. *World J Urol*, Volume 21

---

## BOOK CHAPTERS

1. **Kerbel, R.S., and Theodorescu, D.** 1990. Tumor cell subpopulation interactions mediated by transforming growth factor beta may contribute to clonal dominance of metastatically competent cells in primary tumors, p.100-113. In M.M. Burger, B. Sordat, and R.M. Zinkernagel (eds.), *Cell Cell Interaction* Karger, Basel.

2. **Theodorescu, D., and See W** 1999. Chapter 2: Biology and molecular aspects of development and progression of bladder cancer. In M. J. Droller (ed.), *Bladder cancer: current diagnosis and treatment*. (in press)
3. **Theodorescu, D., and Krupsky, T** 2000. Prostate cancer: Overview of biology, pathology, diagnosis and natural history. In M. J. Zevitz (ed.), *E-Medicine Textbook of Urology* ([www.emedicine.com](http://www.emedicine.com))
4. **Theodorescu, D., and Krupsky, T** 2000. Prostate cancer: Management of localized disease. In M. J. Zevitz (ed.), *E-Medicine Textbook of Urology* ([www.emedicine.com](http://www.emedicine.com))
5. **Theodorescu, D., and Krupsky, T** 2000. Prostate cancer: Brachytherapy. In M. J. Zevitz (ed.), *E-Medicine Textbook of Urology* ([www.emedicine.com](http://www.emedicine.com))
6. **Theodorescu, D., and Coblenz, T** 2000. Bladder cancer. In M. Schwab (ed.), *Cancer Encyclopedia*. Springer, New York
7. **Theodorescu, D.** 2000. Prostate cancer. In M. Schwab (ed.), *Cancer Encyclopedia*. Springer, New York
8. **Nicholson, B and Theodorescu, D.** 2002. Chapter 25: Retroperitoneal Diseases. In Gillenwater, Grayhack, Howards, and Mitchell (eds.), *Adult and Pediatric Urology, 4<sup>th</sup> edition*.
9. **Nicholson, B and Theodorescu, D.** 2002. Chapter 15: Molecular Therapeutics: Present and Future. In Godec, and Mydlo (eds.), *Handbook of prostate cancer: biology, epidemiology, and therapeutic modalities 1<sup>st</sup> edition*.
10. **Myers, C. E. and Theodorescu, D.** 2002. Chapter 16: Orthomolecular and Herbal Therapies in Prostate Cancer. In Godec, and Mydlo (eds.), *Handbook of prostate cancer: biology, epidemiology, and therapeutic modalities 1<sup>st</sup> edition*.
11. **Theodorescu, D.** 2003. Chapter 3: Molecular Pathogenesis of Proliferative and Progressive (Invasive) Urothelial Cancer. In M. J. Droller (ed.), *American Cancer Society Atlas of Clinical Oncology: Bladder Cancer*.
12. **Theodorescu, D. and Cohen, S.M.** 2004. Chapter 2: Molecular Epidemiology. In M. J. Droller and A. P. Bassi (eds.), *Bladder Cancer: From the Laboratory to Clinical Practice*.
13. **Titus, B, Schalken J and Theodorescu, D.** 2005. Biomarkers of Invasion and Metastases. In Lerner SP, Schoenberg M, Sternberg C (Eds): *Textbook of Bladder Cancer*. London: T&F-Informa.

---

#### **OTHER PUBLICATIONS (Extended Abstracts, Non Indexed Publications)**

---

1. **Theodorescu, D., and Kerbel, R.S.** 1989. Overgrowth of metastatic cells in a primary tumor is mediated by nonmetastatic cells via transforming growth factor beta. p.403-405. In M. Pannell (ed.), *Surgical Forum*. American College of Surgeons, Chicago.
2. **Theodorescu, D., Jones, P.A. and Kerbel, R.S.** 1992. Elucidation of the roles of ha-ras and p53 in bladder cancer progression using a novel orthotopic assay system. *Grand Rounds in Urology* 1(3):1-6
3. **Gardner, T. A., Boyd, J. C. and Theodorescu, D.**, 1997 Factors predicting hospital length of stay in patients treated by radical prostatectomy. p.597-600. In S. Schwartz (ed.), *Surgical Forum*. American College of Surgeons, Chicago.

4. **Gray, M. and Theodorescu, D.** 1997 Quality of life following radical prostatectomy: comparison of retropubic and perineal techniques. p.395-399. In S. Schwartz (ed.), *Surgical Forum*. American College of Surgeons, Chicago.
5. **Theodorescu, D. and Lippert, M. C.** The ileal neobladder with a chimney and neourethral tube: A versatile modification. p.133-137. In S. Schwartz (ed.), *Surgical Forum*. American College of Surgeons, Chicago.
6. **Gardner, T. A., and Theodorescu, D.** 1997. Diagnosis and Treatment of Prostate Cancer. *Surgical Services Management* 3 (12): 20-28
7. **Harding M. and Theodorescu, D.** 2000 Molecular prognostic markers for adenocarcinoma of the prostate: News and Views. *Urologic Oncology*
8. **Theodorescu, D.** 2000 Comparison of quality of life in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *AUA News*
9. **Theodorescu, D., Gillenwater, J.Y., and Koutrouvelis, P.G.** 2001. Prostatourethral-rectal fistula formation following prostate brachytherapy: incidence and risk factors. *Medical Updates, on Therapy, Diagnosis and Prevention*
10. **Theodorescu, D.,** Prostate cancer staging: Should MR Imaging be used? 2001 *Journal of Evidence-based Oncology*
11. **Theodorescu, D.** 2001 Alternative medicine use in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *AUA News*
12. **Theodorescu, D.** 2002 The management of carcinoma in situ (CIS) of the bladder. *AUA News*
13. **Theodorescu, D., Rabbani, F. Donat M.** 2004. Followup in Urologic Oncology: A Practical Guide *AUA Updates*.
14. **Theodorescu, D.,** 2004. Cryotherapy for Cancer: Evolution and Science. *Med Reviews*
15. **Sims, T and Theodorescu, D.,** 2004. Treating Bladder Cancer in 2004. *Coping Magazine*.

---

#### **ABSTRACTS, POSTERS, PRESENTATIONS**

1. **Blair, G.K., R.M. Filler, and D. Theodorescu.** 1987. Neonatal Pharyngoesophageal Perforation Mimicking Esophageal Atresia. *Canadian Association for Pediatric Surgery* . Halifax, Abstr 120.
2. **deHarven, E.P., J.G. Connolly, G. Bootsma, and D. Theodorescu.** 1988. Expression of ABH Antigens in Superficial Bladder Cancer. *Canadian Urological Association 43rd Annual Meeting*, Abstr 45.
3. **Theodorescu, D. and J.G. Connolly.** 1989. The Nature of the Prostatic Fossa Lining after Modified Camay Procedure with Intestinal Anastomosis to the Prostatic Capsule. *J. Urol.* 141, 4(2). Abstr 831.
4. **Binnington, A.G., D. Theodorescu, S. Landi, and J.G. Connolly.** 1989. Isolation of Bacille Calmette-Guerin in the Bladder after Intravesical Instillation : An Experimental Model. *J. Urol.* 141, 4(2) Abstr 1244.
5. **Theodorescu, D., C. Waghorne, D. Rieman, R. Greig, and R.S. Kerbel.** 1989. Selection of Metastatic Cells in Primary Tumors may be Mediated by Altered Responsiveness to TGF-Beta: *Critical Determinants in Cancer Progression and Metastasis*. Houston, Texas, Abstr 121.

6. **Kerbel, R.S., C. Waghorne, M. Breitman, and D. Theodorescu.** 1989. Clonal Dominance of Primary Tumors by Metastatically Competent Cells: Genetic Analysis, Mechanisms, and Biological Implications: *Critical Determinants in Cancer Progression and Metastasis*, Houston, Texas.
7. **Theodorescu, D., I. Cornil, and R.S. Kerbel.** 1990. Non-metastatic Cells Increase the Metastatic Inefficiency of Cryptic Metastatically Competent Variants. *American Association for Cancer Research*, Washington, D.C.
8. **Cornil, I., D. Theodorescu, and R.S. Kerbel.** 1990. Influence of Fibroblast-Malignant Cell Interactions in Tumour Progression, *American Association for Cancer Research*, Washington, D.C.
9. **Theodorescu D., and R.S. Kerbel.** 1990. Overexpression of the Ha-ras Oncogene Induces Bladder Invasion in a Human Superficial Transitional Cell Carcinoma. *The Royal College of Physicians and Surgeons of Canada*, Toronto, Ontario, and *Clinical and Investigative Medicine*, Vol 13(4), Abstr 198.
10. **Theodorescu, D., S Witchell, and J.Connolly.** 1990. Chronic Adult Renal Vein Thrombosis: Two Unusual Cases and a Review of the Literature. *The Royal College of Physicians and Surgeons of Canada*, Toronto, Ontario, and *Clinical and Investigative Medicine*, Vol 13(4), Abstr 347.
11. **Fu, X., D. Theodorescu, R.S. Kerbel, and R.M. Hoffman.** 1991. Extensive Multi Organ Metastasis in a Nude Mouse from Orthotopically Onplanted Human Bladder Carcinoma Cell Line Tissue. *American Association for Cancer Research*, Houston , Texas.
12. **Spearman, M.A., D. Theodorescu, A.H. Greenberg, R.S. Kerbel, and J.A. Wright.** 1991. Reduction in Transforming Growth Factor Beta-1 Activity in Metastatic 10T1/2 Fibroblasts using an Antisense Vector. *U.C.L.A. Symposium on Gene Regulation by Antisense RNA and DNA*. Frisco, California.
13. **Theodorescu D., C. Graham, and R.S. Kerbel.** 1991. Overexpression of the Ha-ras Oncogene Induces Upregulation of EGF-Receptors in a Human Superficial Transitional Cell Carcinoma. *European Society for Urological Oncology and Endocrinology*, Marseille, France.
14. **Theodorescu D., and R.S. Kerbel.** 1991. Overexpression of the Ha-ras Oncogene Induces Upregulation of EGF-Receptors in a Human Superficial Transitional Cell Carcinoma. *American Urological Association*, Toronto, Ontario.
15. **Brattain, M.G., S. Wu, L. Sun, D. Theodorescu, R.S. Kerbel, K.M. Mulder, and J.K.V. Willson.** 1992. TGF-B1 Suppresses Tumour Formation by Colon Carcinoma FET Cells in an Autocrine Manner. *American Association for Cancer Research*, San Diego, California.
16. **Theodorescu, D., Y. Tsai, E. Skinner, R.S. Kerbel, and P.A. Jones.** 1992. Expression of a mutated p53 Gene induces the Invasive Phenotype in a Human Transitional Cell carcinoma. *Fourth International Congress of The Metastasis Research Society*, Paris, France.
17. **Theodorescu, D., Y. Tsai, E. Skinner, R.S. Kerbel, and P.A. Jones.** 1992. The Role of a mutated p53 gene in inducing the Invasive Phenotype in Human TCC. *American Urological Association-Notheastern Section*, Toronto, Ontario.
18. **Theodorescu, D., H. Sampson, R. Gupta, M. A. S. Jewett, and J. Trachtenberg.** 1995. Pelvic Lymphadenectomy in Prostate Cancer : comparison of surgical techniques. *American Urological Association*, Las Vegas, Nevada.
19. **Theodorescu, D., W. R. Fair, H. W. Herr, P. C. Sogani, J. Sheinfeld, G. Dalbagni, and Paul Russo** 1995. Expectant management of patients with T1-4N0M0 penile cancer. *American Urological Association*, Las Vegas, Nevada.

20. Theodorescu, D., E. E. de Lange, and J. P. Mugler. 1996. Breath Hold Flow-Compensated 2D Magnetization-Prepared Gradient-Echo (MP-GRE) MR Angiography in the diagnosis and staging of caval involvement by renal cell carcinoma. *American Urological Association*, Orlando, Florida.
21. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E. and Frierson, H. W. 1997 The use of p53, bcl-2 and Rb protein expression as prognostic markers in localized carcinoma of the prostate. *American Urological Association*, New Orleans, Louisiana.
22. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E. and Frierson, H. W. 1997 Cathepsin D and Chromogranin expression as prognostic markers in patients treated by radical prostatectomy. *American Urological Association*, New Orleans, Louisiana.
23. Theodorescu, D. and Gulding, K. M. 1997 Expression of the epidermal growth factor receptor (EGFR) mediates the growth and motility of bladder cancer cells. *American Urological Association*, New Orleans, Louisiana.
24. Gray, M. and Theodorescu, D. 1997 Continence following radical prostatectomy: comparison of retropubic and perineal techniques. *American Urological Association*, New Orleans, Louisiana.
25. Lippert, M. C., Broder, S. R., Boyd, J. C. and Theodorescu, D., 1997 Early PSA failure following radical prostatectomy: The importance of surgical technique. *American Urological Association*, New Orleans, Louisiana.
26. Gardner, T. A., Boyd, J. C. and Theodorescu, D., 1997 Factors predicting hospital length of stay in patients treated by radical prostatectomy. *American College of Surgeons*, Chicago, Illinois.
27. Gray, M. and Theodorescu, D. 1997 Quality of life following radical prostatectomy: comparison of retropubic and perineal techniques. *American College of Surgeons*, Chicago, Illinois.
28. Theodorescu, D. and Lippert, M. C. 1997 The ileal neobladder with a chimney and neourethral tube: A versatile modification. *American College of Surgeons*, Chicago, Illinois.
29. Gardner, T. A., Boyd, J. C. and Theodorescu, D., 1998 Factors predicting hospital length of stay in patients treated by radical prostatectomy. *American Urological Association*, San Diego, California.
30. Theodorescu, D. and Gulding, K. M. 1998. Inhibition of human bladder cancer motility by genistein is dependent on epidermal growth factor receptor but not ras gene expression. *American Urological Association*, San Diego, California.
31. Theodorescu, D., Frierson, H. W. and Sikes R. A. 1998. Molecular analysis of surgical margins following radical prostatectomy for localized prostate cancer. *American Urological Association*, San Diego, California.
32. Harding M. and Theodorescu, D. 1998. The role of vascular endothelial growth factor (VEGF) in prostate cancer growth and metastasis. *American Urological Association*, San Diego, California.
33. Fulmer, B., Frierson, H. W., Petroni G, and Theodorescu, D. 1998. PSA velocity at tumor recurrence following radical prostatectomy: a surrogate marker for increased tumor aggressiveness in African American men. 17th *UICC International Cancer Congress*, Rio de Janeiro, Brasil.
34. Crane, C. H., Clark M., Petroni, G., and Theodorescu, D. 1998. The Bladder Tumor Antigen (BTA) test: performance in patients undergoing pelvic irradiation for non bladder malignancies. 17th *UICC International Cancer Congress*, Rio de Janeiro, Brasil.
35. Broder, S. R., Frierson, H. W., Petroni, G, and Theodorescu D. 1998. P53, Rb proteins and area weighted microvessel density are long term survival markers in localized carcinoma of the prostate. 17th *UICC International Cancer Congress*, Rio de Janeiro, Brasil.

36. **Gildea, J. J., Golden, W., Harding, M. A., and Theodorescu D.** 1999. The phenotypic and cytogenetic analysis of t24t, a highly tumorigenic subline of the human bladder cancer cell line t24. *American Urological Association*, Dallas, Texas.
37. **Sheta, E. A., Harding, M. A., and Theodorescu, D.** 1999. Vascular endothelial growth factor is transcriptionally regulated by cell density in prostate cancer cells. *American Urological Association*, Dallas, Texas.
38. **Bissonette, E., Lippert, M. C., Petroni, G., Theodorescu, D.** 1999. Comparison of quality of life in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *American Urological Association*, Dallas, Texas.
39. **Lippert, M. C., and Theodorescu, D.** 1999. Alternative Medicine Use in Patients Treated With Curative Intent for Localized Prostate Cancer. *American Urological Association*, Dallas, Texas.
40. **Bailey G., Klotz L., Foster, R., Theodorescu, D., and Bell, D.** 1999. Treatment wait times in patients with muscle invasive bladder cancer: Comparison of Canadian and American university centers. *Canadian Urological Association*, Halifax, Nova Scotia.
41. **Gildea, J. J., Chen, C, Dong, J-T., and Theodorescu D.** 2000. Suppression of motility of a human bladder cancer cell line by wild type PTEN/MMAC is dependent on its protein phosphatase activity. *American Urological Association*, Atlanta, Georgia.
42. **Theodorescu, D., Gillenwater, J.Y., and Koutrouvelis, P.G.** 2000. Prostatourethral-rectal fistula formation following prostate brachytherapy: incidence and risk factors. *American Urological Association*, Atlanta, Georgia.
43. **Krupsky, T., Harding, M. A., and Theodorescu, D.** 2000. Mutant p53 induces VEGF and PSA transcription in prostate cancer cells and this is synergistic with androgen. *American Urological Association*, Atlanta, Georgia.
44. **Fulmer, B., Petroni G, and Theodorescu, D.** 2000. Prospective comparison of sexual and voiding function in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *American Urological Association*, Atlanta, Georgia.
45. **Chapman, T., Bissonette, E., Petroni, G., Theodorescu, D.** 2000 Comparison of procedural costs in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer. *American Urological Association*, Atlanta, Georgia.
46. **Krupsky, T., Harding, M. A., and Theodorescu, D.** 2000. Mutant p53 induces VEGF and PSA transcription in prostate cancer cells and this is synergistic with androgen. *American Urological Association-Mid Atlantic Section*, San-Juan, Puerto Rico.
47. **Coblentz, T., Mills, S. E. and Theodorescu, D.** 2000. The value of second opinion pathology in the evaluation of patients referred for radical cystectomy. *American Urological Association-Mid Atlantic Section*, San-Juan, Puerto Rico.
48. **Seraj, M. J., Gildea, J. J., Harding, M. A., and Theodorescu, D.** 2001. Molecular determination of perivesical and lymph node metastasis following radical cystectomy for urothelial carcinoma of the bladder. *American Urological Association*, Anaheim, California.
49. **Valicenti, R. K., Bissonette, E., Petroni, G., and Theodorescu, D.** 2001. Prospective Comparison of Sexual Function and Satisfaction Between 3D Conformal Radiation Therapy and Transperineal Prostate Brachytherapy. *American Urological Association*, Anaheim, California.

50. Smith, E. Frierson, H. F., Mills, S. E., and Theodorescu, D. 2001. Gleason scores of prostate biopsy and radical prostatectomy specimens over a 10 period: Is there any evidence for systematic upgrading ? *American Urological Association-Mid Atlantic Section*, Harrisonburg, Virginia.
51. Smith, E., Bissonette, E., Theodorescu, D. 2002. Comparison of quality of life in patients treated by either radical prostatectomy or brachytherapy for clinically localized prostate cancer: Long Term Results. *American Urological Association*, Orlando, Florida.
52. Maklouf, A., Bissonette, E., and Theodorescu, D., 2002. Comparison of the costs and charges associated with multimodality radiotherapy and radical prostatectomy in the treatment of clinically localized prostate cancer: *American Urological Association*, Orlando, Florida.
53. Miller, N. Bissonette, E., and Theodorescu, D. 2002. The impact of neoadjuvant hormonal therapy on the quality of life of patients treated by brachytherapy for clinically localized prostate cancer *American Urological Association-Mid Atlantic Section*, Baltimore, Maryland.
54. Gildea, J. J., Chen, C, Dong, J-T., and Theodorescu D. 2003. Suppression of motility of a human bladder cancer cell line by wild type PTEN/MMAC is dependent on its protein phosphatase activity. *American Urological Association*, Chicago, Illinois.
55. Nicholson B.E., Harding, M.A., Lynch, K.R. and Theodorescu D. 2003. Lysophosphatidic acid receptors and prostate cancer-the role of the lpa3 receptor in tumor growth. *American Urological Association*, Chicago, Illinois.
56. Nicholson B.E., Seraj, J. and Theodorescu D. 2003. Gene expression changes induced by the metastasis suppressor rhogd12 in the t24t bladder cancer cell line. *American Urological Association*, Chicago, Illinois.
57. Nicholson B.E., Harding, M.A., Seraj, J. and Theodorescu D. 2003. A novel bladder cell progression model and gene expression profile: the fl series. *American Urological Association*, Chicago, Illinois.
58. Nicholson B.E., Harding, M.A., Lynch, K.R. and Theodorescu D. 2003. Lysophosphatidic acid receptors and prostate cancer-the role of the lpa3 receptor in tumor growth. *American Urological Association*, Chicago, Illinois.
59. Gildea, J.J., Harding, M.A., and Theodorescu D. 2003. RHOGDI2 is an invasion and metastasis suppressor gene in human cancer. *American Urological Association*, Chicago, Illinois.
60. Miller, N. Bissonette, E., and Theodorescu, D. 2003. Multimodality Radiotherapy and Androgen Ablation In the Treatment Of High Risk Patients With Clinically Localized Prostate Cancer *American Urological Association-Mid Atlantic Section*, Boca Raton, Florida.
61. Maklouf, A., Slingluff, C., and Theodorescu, D., 2003. Antigen presentation on prostate cancer cells. *American Urological Association-Mid Atlantic Section*, Boca Raton, Florida.
62. Raja, P., Lippert, MC., Theodorescu, D., and Schneider, B. 2003. Are there significant advantages to intraoperative planning compared to preoperative planning for permanent prostate seed implants? *24th American Brachytherapy Society Meeting*.
63. Titus, B. Bissonette, E., and Theodorescu, D. 2004. The mechanism of action of RhoGDI1, a novel metastasis suppressor gene in bladder cancer *American Urological Association-Mid Atlantic Section*, San Francisco, California.
64. Bigler, D., Harding, M., and Theodorescu, D. 2004. The role of Rap2 in androgen independent prostate cancer. *American Association of Cancer Reserach*, Orlando, Florida.